Aadi Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Aadi Bioscience has a total shareholder equity of $68.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $85.7M and $16.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$62.62m |
Equity | US$68.87m |
Total liabilities | US$16.83m |
Total assets | US$85.70m |
Recent financial health updates
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?
Jul 02Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Feb 12Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Oct 03Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Jun 28Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Mar 04Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Jul 06Recent updates
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop
Jul 03Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?
Jul 02Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)
May 10Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified
Mar 07Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Feb 12Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge
Dec 16Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results
Nov 10Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Oct 03Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Jun 28Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Mar 04Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors
Oct 12A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)
Sep 28Aadi Bioscience: Taking mTOR Inhibition To The Next Level
Sep 21Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Jul 06Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes
Jun 23What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today
Nov 27Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning
Nov 25Financial Position Analysis
Short Term Liabilities: AADI's short term assets ($77.3M) exceed its short term liabilities ($15.8M).
Long Term Liabilities: AADI's short term assets ($77.3M) exceed its long term liabilities ($1.0M).
Debt to Equity History and Analysis
Debt Level: AADI is debt free.
Reducing Debt: AADI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AADI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AADI has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 38.2% each year.